Brief: Nykode Therapeutics To Regain Control Of VB10.Neo Program
Nov 7 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS TO REGAIN CONTROL OF VB10.NEO PROGRAM
* NYKODE THERAPEUTICS ASA - IS NOT REQUIRED TO REFUND ANY
UPFRONT
PAYMENTS OR MAKE ANY FUTURE PAYMENTS TO GENENTECH ON TERMINATION
* NYKODE THERAPEUTICS ASA - EXISTING COLLABORATION AND
LICENSING
AGREEMENT SIGNED SEPTEMBER 2020 WILL TERMINATE EFFECTIVE JANUARY
6, 2025
Source text: ID:nObiq2jhqa
Further company coverage: NYKD.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026